Phase INeuropeptide
Compound 61596
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061596
Risk Class
MODERATE
Last Audit
Apr 28, 2108
Research Abstract
Neuropeptide candidate engineered for cognitive resilience initiatives with automated dossier coverage.
Compound 61596 is a neuropeptide asset inside neuropeptide innovation track initiatives, optimized for cognitive resilience and neuroprotection.
The dossier currently sits in phase i with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061596 with updates logged 2108-04-28.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Cognitive resilienceNeuroprotection
Nomenclature
CX-61596Neuropeptide Program 61596
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061596
- [2] Operations Pulse • Neuropeptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61596